<DOC>
	<DOCNO>NCT00988364</DOCNO>
	<brief_summary>The purpose study : - To identify common factor L5 prevalence patient Metabolic Syndrome . - To determine whether Ezetimibe , Simvastatin , Vytorin correct L5- promote factor reduce L5 Metabolic Syndrome patient .</brief_summary>
	<brief_title>Effects Ezetimibe , Simvastatin , Vytorin Reducing L5 Subfraction LDL Patients With Metabolic Syndrome .</brief_title>
	<detailed_description>Epidemiological evidence indicate metabolic syndrome ( MS ) strong predispose condition atherosclerosis . Elevation plasma low-density lipoprotein ( LDL ) cholesterol ( LDL-C ) concentration important risk factor atherosclerosis ; however , LDL-C elevation criterion metabolic syndrome , raise question LDL 's role syndrome 's association atherosclerosis . L5 , highly electronegative mildly oxidized LDL subfraction recently isolate hypercholesterolemic human plasma , may provide key answer question . In cultured vascular endothelial cell ( EC ) , L5 inhibit proliferation induces apoptosis monocyte-EC adhesion . In preliminary study , L5 could also detect patient MS without elevate LDL-C. Because LDL subfractions harmless EC , presence MS-L5 prompt u hypothesize atherogenic role LDL solely determine plasma LDL-C concentration , importantly , composition . The propose study design test hypothesis . The first question address lipid factor determines prevalence L5 MS . Subsequently , examine whether treatment select medicine effectively reduce L5 MS patient correct factor favorable L5 formation . We process identify active component L5 fully characterize atherogenic role L5 MS , . In current proposal , focus interest efficacy Ezetimibe , Simvastatin , Vytorin reduce L5 plasma MS patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Participants meet 3 5 criterion specify ATPIII guideline recruit . The 5 criterion : 1. abdominal obesity ( men &gt; 40 inch , woman &gt; 35 inch ) ; 2 . TG &gt; 150mg/dL ; 3. low HDLC ( men &lt; 40mg/dL , woman &lt; 50 mg/dL ) ; 4. high blood pressure ( &gt; or=130/ &gt; or=85 mmHg ) ; 5. fast glucose &gt; = 110mg/dL . People different ethnic background include . symptomatic coronary artery disease peripheral vascular disease cerebral ischemia ( stroke ) smoking hypothyroidism kidney diseases consumption antioxidation supplements/drugs use lipidlowering drug last 3 month woman pregnant , nursing , plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>LDL subfraction L5</keyword>
	<keyword>The reduction LDL Chol patient Metabolic Syndrome</keyword>
	<keyword>The prevalence L5 patient Metabolic Syndrome</keyword>
	<keyword>The reduction L5 subfraction patient Metabolic Syndrome</keyword>
</DOC>